NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT02954172,Evaluate the Efficacy and Safety of IBI305 in Patients With Advanced or Recurrent Non-squamous NSCLC,https://clinicaltrials.gov/study/NCT02954172,,COMPLETED,"A randomized, double blind, multicenter phase3 study .",YES,NSCLC,DRUG: Bevacizumab in Combination With Paclitaxel/Carboplatin|DRUG: IBI305 in Combination with Paclitaxel/Carboplatin,"Objective Response Rate, ORR（objective response rate）was defined as the percentage of participants in the analysis population who had a Complete Response or a Partial Response per RECIST 1.1. The percentage of participants who experienced a CR or PR is presented. Overall Response (OR) = CR + PR., 18 weeks","Overall Survival Time, OS was defined as the time from randomization to death due to any cause., 18.020 months|Progression-free Survival, Progression-Free Survival (PFS) Per RECIST 1.1 as Assessed by Independent Radiological Review Committee.Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions, 18 months",,Innovent Biologics (Suzhou) Co. Ltd.,WuXi CDS Clinical Research (Shanghai) Co.Ltd.,ALL,"ADULT, OLDER_ADULT",PHASE3,450,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",CIBI305A301,2016-11-28,2018-10-19,2019-11-12,2016-11-03,2020-12-08,2020-12-08,"Cancer Center; Sun Yat sen University;, Guangzhou, Guangdong, 510060, China","Statistical Analysis Plan, https://cdn.clinicaltrials.gov/large-docs/72/NCT02954172/SAP_000.pdf|Study Protocol, https://cdn.clinicaltrials.gov/large-docs/72/NCT02954172/Prot_001.pdf"
